Inside the research

Enovis Corporation

ENOV Research profile · latest available data

Price overview

$18.46

▲ +0.19 (+1.0%)

52w hi$32.87
52w lo$17.80
Vol1.06M
As of25 Sep 2026

The Verdict

Hold

Our score -0.36

Short-0.30
Medium-0.31
Long-0.60

computed 2026-09-27

Key fundamentals

Enovis Corporation

Healthcare · Medical Devices

Market cap$1.06B
Enterprise value$2.42B
Forward P/E5.00x
EV / EBITDA6.38x
P / S (ttm)0.46x
Profit margin-48.0%
Return on equity-54.1%
Revenue growth+3.2%
Debt / equity92.56

Layer Breakdown

LayerRawContribution
Fundamental-0.06
Sector+0.08
Technical-0.26
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

United States · www.enovis.com

Risk Metrics

Beta vs SPX1.41
Corr SPX0.41
Annual vol55.3%
Annual ret-27.7%
Sharpe-0.50
Max DD-63.9%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-05-19Officer / Director Change, Shareholder Vote…read
2026-05-07Earnings Release, Exhibitsread
2026-02-26Earnings Release, Exhibitsread
2026-01-12Reg FD Disclosure, Exhibitsread
2025-12-15Officer / Director Changeread
2025-12-10Material Agreement, Material Obligation…read
2025-11-14Officer / Director Changeread
2025-11-06Earnings Release, Exhibitsread
2025-08-07Earnings Release, Exhibitsread
2025-05-21Shareholder Voteread
2025-05-08Earnings Release, Exhibitsread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share98.0%
HHI3,608 (concentrated)

Top Holders

HolderValueShares
Capital Research / Capital World$58.48M2.82M
Millennium Management$16.63M803.32K
AQR Capital Management$12.23M590.65K
State Street Corp$10.96M11.28M
Fidelity / FMR LLC$4.75M4.95M
Bridgewater Associates$1.60M77.09K
Citadel Advisors$525.78K25.40K
T. Rowe Price Group$1.64K79.42K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-068-Kview
2026-08-0610-Qview
2026-07-014view
2026-06-2611-Kview
2026-06-164view
2026-06-154view
2026-06-114view
2026-06-034view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view
2026-05-214view

The Long Run

FY 2011–2025 · 14 years

LineLatestCAGRTrend
Revenue$2.25B+11.8%
Gross profit$990.78M+11.5%
Operating income-$775.72M+29.0%
Net income-$33.26M+28.2%
Cash from ops$217.29M+12.9%

Indices

S&P SmallCap 600

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$18.31$18.79$18.06$18.461.06M
Sep 24$18.32$18.50$17.68$18.271.72M
Sep 23$18.29$18.56$17.86$18.241.18M
Sep 22$18.45$18.65$18.13$18.391.79M
Sep 21$18.18$18.18$17.48$18.042.59M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →